Hasan Alkomiet, Falkai Peter, Wobrock Thomas, Lieberman Jeffrey, Glenthøj Birte, Gattaz Wagner F, Thibaut Florence, Möller Hans-Jürgen
a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University , Munich , Germany.
b Centre of Mental Health, Darmstadt-Dieburg Clinics , Groß-Umstadt , Germany.
Int J Psychiatry Clin Pract. 2017 Jun;21(2):82-90. doi: 10.1080/13651501.2017.1291839. Epub 2017 Feb 24.
Schizophrenia is a severe mental disorder and many patients are treated in primary care settings. Apart from the pharmacological management of disease-associated symptoms, the detection and treatment of side effects is of the utmost importance in clinical practice. The purpose of this publication is to offer relevant evidence-based recommendations for the biological treatment of schizophrenia in primary care.
This publication is a short and practice-oriented summary of Parts I-III of the World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. The recommendations were developed by the authors and consented by a task force of international experts. Guideline recommendations are based on randomized-controlled trials and supplemented with non-randomized trials and meta-analyses where necessary.
Antipsychotics of different chemical classes are the first-line pharmacological treatments for schizophrenia. Specific circumstances (e.g., suicidality, depression, substance dependence) may need additional treatment options. The pharmacological and non-pharmacological management of side effects is of crucial importance for the long-term treatment in all settings of the healthcare system.
This summary of the three available evidence-based guidelines has the potential to support clinical decisions and can improve treatment of schizophrenia in primary care settings.
精神分裂症是一种严重的精神障碍，许多患者在初级保健机构接受治疗。除了对疾病相关症状进行药物治疗外，副作用的检测和治疗在临床实践中至关重要。本出版物的目的是为初级保健中精神分裂症的生物治疗提供相关的循证建议。
本出版物是世界生物精神病学协会联合会（WFSBP）精神分裂症生物治疗指南第一至三部分的简短且注重实践的总结。这些建议由作者制定，并经国际专家特别工作组认可。指南建议基于随机对照试验，并在必要时辅以非随机试验和荟萃分析。
不同化学类别的抗精神病药物是精神分裂症的一线药物治疗方法。特定情况（如自杀倾向、抑郁、物质依赖）可能需要其他治疗选择。副作用的药物和非药物管理对于医疗系统所有环境中的长期治疗至关重要。
这一现有循证指南的总结有潜力支持临床决策，并可改善初级保健环境中精神分裂症的治疗。
